Journal of Neuro-Oncology

, Volume 97, Issue 1, pp 137–141 | Cite as

Hepatic Sinusoidal Obstruction Syndrome in a child after chemotherapy for medulloblastoma

  • M. Kashif Ishaqi
  • A. Jamil
  • M. Khanani
  • M. Baroudi
  • Omar Trad
  • M. El-Hayek
  • Eric Bouffet
Case Report


Hepatic Sinusoidal Obstruction Syndrome (HSOS), the new name given to veno-occlusive disease (VOD) of the liver, is a well-known complication of high-dose chemotherapy employed with hematopoietic stem cell transplantation, but it has rarely been observed in children who receive conventional chemotherapy. HSOS following standard chemotherapy has been reported in patients receiving vincristine, actinomycin D, and cyclophosphamide for the treatment of Wilms tumor and more rarely rhabdomyosarcoma. We report a 14-year-old boy with high risk medulloblastoma treated with craniospinal radiation followed by chemotherapy, who experienced severe HSOS after only one course of chemotherapy including carboplatin, vincristine, and cyclophosphamide. To our knowledge, this is the second report of HSOS after standard dose chemotherapy for brain tumor in childhood.


Chemotherapy Hepatic Sinusoidal Obstruction Syndrome Medulloblastoma Veno-occlusive disease 


  1. 1.
    Kumar S, DeLeve LD, Kamath PS, Tefferi A (2003) Hepatic veno-occlusive disease (sinusoidal obstruction syndrome) after hematopoietic stem cell transplantation. Mayo Clin Proc 78:589–598CrossRefPubMedGoogle Scholar
  2. 2.
    Tack DK, Letendre L, Kamath PS, Tefferi A (2001) Development of hepatic veno-occlusive disease after Mylotarg infusion for relapsed acute myeloid leukemia. Bone Marrow Transpl 28:895–897CrossRefGoogle Scholar
  3. 3.
    Jones RJ, Lee KS, Beschorner WE, Vogel VG, Grochow LB, Braine HG, Vogelsang GB, Sensenbrenner LL, Santos GW, Saral R (1987) Venoocclusive disease of the liver following bone marrow transplantation. Transplantation 44:778–783CrossRefPubMedGoogle Scholar
  4. 4.
    McDonald GB, Hinds MS, Fisher LD, Schoch HG, Wolford JL, Banaji M, Hardin BJ, Shulman HM, Clift RA (1993) Veno-occlusive disease of the liver and multiorgan failure after bone marrow transplantation: a cohort study of 355 patients. Ann Intern Med 118:255–267PubMedGoogle Scholar
  5. 5.
    McDonald GB, Sharma P, Matthews DE, Shulman HM, Thomas ED (1984) Venocclusive disease of the liver after bone marrow transplantation: diagnosis, incidence, and predisposing factors. Hepatology 4:116–122CrossRefPubMedGoogle Scholar
  6. 6.
    Shulman HM, Fisher LB, Schoch HG, Henne KW, McDonald GB (1994) Veno-occlusive disease of the liver after marrow transplantation: histological correlates of clinical signs and symptoms. Hepatology 19:1171–1181CrossRefPubMedGoogle Scholar
  7. 7.
    Valteau-Couanet D, Fillipini B, Benhamou E, Grill J, Kalifa C, Couanet D, Habrand JL, Hartmann O (2005) High-dose busulfan and thiotepa followed by autologous stem cell transplantation (ASCT) in previously irradiated medulloblastoma patients: high toxicity and lack of efficacy. Bone Marrow Transpl 36:939–945CrossRefGoogle Scholar
  8. 8.
    Brock PR, Bellman SC, Yeomans EC, Pinkerton CR, Pritchard J (1991) Cisplatin ototoxicity in children: a practical grading system. Med Pediatr Oncol 19:295–300CrossRefPubMedGoogle Scholar
  9. 9.
    Ringden O, Remberger M, Lehmann S, Hentschke P, Mattsson J, Klaesson S, Aschan J (2000) N-acetylcysteine for hepatic veno-occlusive disease after allogeneic stem cell transplantation. Bone Marrow Transpl 25:993–996CrossRefGoogle Scholar
  10. 10.
    Wilmot FC, Robertson GW (1920) Senecio disease, or cirrhosis of the liver due to senecio poisoning. Lancet 2:848–849CrossRefGoogle Scholar
  11. 11.
    Berk PD, Popper H, Krueger GR, Decter J, Herzig G, Graw RG Jr (1979) Veno-occlusive disease of the liver after allogeneic bone marrow transplantation: possible association with graft-versus-host disease. Ann Intern Med 90:158–164PubMedGoogle Scholar
  12. 12.
    Kalayoglu-Besisik S, Yenerel MN, Caliskan Y, Ozturk S, Besisik F, Sargin D (2005) Time-related changes in the incidence, severity, and clinical outcome of hepatic veno-occlusive disease in hematopoietic stem cell transplantation patients during the past 10 years. Transpl Proc 37:2285–2289CrossRefGoogle Scholar
  13. 13.
    Shih CS, Hale GA, Gronewold L, Tong X, Laningham FH, Gilger EA, Srivastava DK, Kun LE, Gajjar A, Fouladi M (2008) High-dose chemotherapy with autologous stem cell rescue for children with recurrent malignant brain tumors. Cancer 112:1345–1353CrossRefPubMedGoogle Scholar
  14. 14.
    Bisogno G, de Kraker J, Weirich A, Masiero L, Ludwig R, Tournade MF, Carli M (1997) Veno-occlusive disease of the liver in children treated for Wilms tumor. Med Pediatr Oncol 29:245–251CrossRefPubMedGoogle Scholar
  15. 15.
    Czauderna P, Katski K, Kowalczyk J, Kurylak A, Lopatka B, Skotnicka-Klonowicz G, Sawicz-Birkowska K, Godzinski J (2000) Venoocclusive liver disease (VOD) as a complication of Wilms’ tumour management in the series of consecutive 206 patients. Eur J Pediatr Surg 10:300–303CrossRefPubMedGoogle Scholar
  16. 16.
    Green DM, Norkool P, Breslow NE, Finklestein JZ, D’Angio GJ (1990) Severe hepatic toxicity after treatment with vincristine and dactinomycin using single-dose or divided-dose schedules: a report from the National Wilms’ Tumor Study. J Clin Oncol 8:1525–1530PubMedGoogle Scholar
  17. 17.
    Tornesello A, Piciacchia D, Mastrangelo S, Lasorella A, Mastrangelo R (1998) Veno-occlusive disease of the liver in right-sided Wilms’ tumours. Eur J Cancer 34:1220–1223CrossRefPubMedGoogle Scholar
  18. 18.
    Cecen E, Uysal KM, Ozguven A, Gunes D, Irken G, Olgun N (2007) Veno-occlusive disease in a child with rhabdomyosarcoma after conventional chemotherapy: report of a case and review of the literature. Pediatr Hematol Oncol 24:615–621CrossRefPubMedGoogle Scholar
  19. 19.
    Kanwar VS, Albuquerque ML, Ribeiro RC, Kauffman WM, Furman WL (1995) Veno-occlusive disease of the liver after chemotherapy for rhabdomyosarcoma: case report with a review of the literature. Med Pediatr Oncol 24:334–340CrossRefPubMedGoogle Scholar
  20. 20.
    Ortega JA, Donaldson SS, Ivy SP, Pappo A, Maurer HM (1997) Venoocclusive disease of the liver after chemotherapy with vincristine, actinomycin D, and cyclophosphamide for the treatment of rhabdomyosarcoma. A report of the Intergroup Rhabdomyosarcoma Study Group. Childrens Cancer Group, the Pediatric Oncology Group, and the Pediatric Intergroup Statistical Center. Cancer 79:2435–2439CrossRefPubMedGoogle Scholar
  21. 21.
    Dunkel IJ, Boyett JM, Yates A, Rosenblum M, Garvin JH Jr, Bostrom BC, Goldman S, Sender LS, Gardner SL, Li H, Allen JC, Finlay JL (1998) High-dose carboplatin, thiotepa, and etoposide with autologous stem-cell rescue for patients with recurrent medulloblastoma Children’s Cancer Group. J Clin Oncol 16:222–228PubMedGoogle Scholar
  22. 22.
    Massimino M, Gandola L, Spreafico F, Luksch R, Collini P, Giangaspero F, Simonetti F, Casanova M, Cefalo G, Pignoli E, Ferrari A, Terenziani M, Podda M, Meazza C, Polastri D, Poggi G, Ravagnani F, Fossati-Bellani F (2006) Supratentorial primitive neuroectodermal tumors (S-PNET) in children: a prospective experience with adjuvant intensive chemotherapy and hyperfractionated accelerated radiotherapy. Int J Radiat Oncol Biol Phys 64:1031–1037PubMedGoogle Scholar
  23. 23.
    Strother D, Ashley D, Kellie SJ, Patel A, Jones-Wallace D, Thompson S, Heideman R, Benaim E, Krance R, Bowman L, Gajjar A (2001) Feasibility of four consecutive high-dose chemotherapy cycles with stem-cell rescue for patients with newly diagnosed medulloblastoma or supratentorial primitive neuroectodermal tumor after craniospinal radiotherapy: results of a collaborative study. J Clin Oncol 19:2696–2704PubMedGoogle Scholar
  24. 24.
    Borowska H, Arciszewska E, Czauderna P, Sawicki B (2004) Dactinomycin-induced veno-occlusive disease in rats. The hepatoprotective action of amifostine. Evaluation in a light and electron microscope. Folia Morphol 63:91–93Google Scholar
  25. 25.
    Elli M, Pinarli FG, Dagdemir A, Acar S (2006) Veno-occlusive disease of the liver in a child after chemotherapy for brain tumor. Pediatr Blood Cancer 46:521–523CrossRefPubMedGoogle Scholar
  26. 26.
    Bakhshi S, Cerosaletti KM, Concannon P, Bawle EV, Fontanesi J, Gatti RA, Bhambhani K (2003) Medulloblastoma with adverse reaction to radiation therapy in Nijmegen breakage syndrome. J Pediatr Hematol Oncol 25:248–251CrossRefPubMedGoogle Scholar
  27. 27.
    Distel L, Neubauer S, Varon R, Holter W, Grabenbauer G (2003) Fatal toxicity following radio- and chemotherapy of medulloblastoma in a child with unrecognized Nijmegen breakage syndrome. Med Pediatr Oncol 41:44–48CrossRefPubMedGoogle Scholar
  28. 28.
    Hirsch B, Shimamura A, Moreau L, Baldinger S, Hag-alshiekh M, Bostrom B, Sencer S, D’Andrea AD (2004) Association of biallelic BRCA2/FANCD1 mutations with spontaneous chromosomal instability and solid tumors of childhood. Blood 103:2554–2559CrossRefPubMedGoogle Scholar
  29. 29.
    de Chadarevian JP, Vekemans M, Bernstein M (1985) Fanconi’s anemia, medulloblastoma, Wilms’ tumor, horseshoe kidney, and gonadal dysgenesis. Arch Pathol Lab Med 109:367–369PubMedGoogle Scholar
  30. 30.
    Frappart PO, McKinnon PJ (2007) BRCA2 function and the central nervous system. Cell Cycle 6:2453–2457PubMedGoogle Scholar
  31. 31.
    Offit K, Levran O, Mullaney B, Mah K, Nafa K, Batish SD, Diotti R, Schneider H, Deffenbaugh A, Scholl T, Proud VK, Robson M, Norton L, Ellis N, Hanenberg H, Auerbach AD (2003) Shared genetic susceptibility to breast cancer, brain tumors, and Fanconi anemia. J Natl Cancer Inst 95:1548–1551PubMedGoogle Scholar
  32. 32.
    Ruud E, Wesenberg F (2001) Microcephalus, medulloblastoma and excessive toxicity from chemotherapy: an unusual presentation of Fanconi anaemia. Acta Paediatr 90:580–583CrossRefPubMedGoogle Scholar
  33. 33.
    Sari N, Akyuz C, Aktas D, Gumruk F, Orhan D, Alikasifoglu M, Aydin B, Alanay Y, Buyukpamukcu M (2009) Wilms tumor, AML and medulloblastoma in a child with cancer prone syndrome of total premature chromatid separation and Fanconi anemia. Pediatr Blood Cancer 53(2):208–210CrossRefPubMedGoogle Scholar
  34. 34.
    Tischkowitz MD, Chisholm J, Gaze M, Michalski A, Rosser EM (2004) Medulloblastoma as a first presentation of Fanconi anemia. J Pediatr Hematol Oncol 26:52–55CrossRefPubMedGoogle Scholar
  35. 35.
    Miralbell R, Lomax A, Bortfeld T, Rouzaud M, Carrie C (1997) Potential role of proton therapy in the treatment of pediatric medulloblastoma/primitive neuroectodermal tumors: reduction of the supratentorial target volume. Int J Radiat Oncol Biol Phys 38:477–484CrossRefPubMedGoogle Scholar
  36. 36.
    Lee CT, Bilton SD, Famiglietti RM, Riley BA, Mahajan A, Chang EL, Maor MH, Woo SY, Cox JD, Smith AR (2005) Treatment planning with protons for pediatric retinoblastoma, medulloblastoma, and pelvic sarcoma: how do protons compare with other conformal techniques? Int J Radiat Oncol Biol Phys 63:362–372CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC. 2009

Authors and Affiliations

  • M. Kashif Ishaqi
    • 1
  • A. Jamil
    • 1
  • M. Khanani
    • 1
  • M. Baroudi
    • 1
  • Omar Trad
    • 1
  • M. El-Hayek
    • 1
  • Eric Bouffet
    • 2
  1. 1.Division of Pediatric Hematology/OncologyTawam Hospital, Johns Hopkins MedicineAl-AinUnited Arab Emirates
  2. 2.Division of Hematology and OncologyHospital for Sick ChildrenTorontoCanada

Personalised recommendations